Info

NexGenix is the leading biotechnology company in the field of neurofibromatosis and is designing innovative drugs for unmet medical needs, using our expertise to develop therapies for the treatment of NF1, NF2, other tumor-causing genetic disorders and related sporadic tumors. Substantial Target Population NF is the most common single gene disorder to affect the nervous system. Over 2 million people worldwide, including over 400,000 people in the Company's target markets, require treatment for NF. NF is more common than the inherited disorders muscular dystrophy, Huntington's disease and cystic fibrosis combined, and represents a clear unmet medical need with a potential market of over $1 billion. Leading Researchers The Company's Scientific Advisory Board is made up of many of the leading researchers in the field of NF. Extensive basic research on the cause of NF has been performed and is the basis of our drug development efforts. Research Facility to Conduct Preclinical Screening The Company has established a research facility in Burlingame, California, with equipment, biological materials and subject-expert scientific staff to perform cell-based assays and animal-based screening. Limited Competition The Company is not aware of other companies focused on drug development for NF. There is no drug treatment currently available for NF1 or NF2. The only option available to patients is surgery or focused beam radiosurgery for vestibular schwannomas in NF2, which in most cases is considered suboptimal. Effective treatments for NF1, NF2 and related sporadic tumors represent a clear unmet medical need. Availability of Government Grants to Support Research and Development The Company plans to fund a portion of its research and development expenses through government funded research programs. The Company has been awarded a $1.1 million grant by the US Department of Defense for NF2 drug development for the period covering 2006-2008. The Company expects to continue to apply for grants to help fund its research and development efforts. Our Technology Provides Unique Advantages The Company's technology includes: mechanistic target identification for NF2; a unique preclinical platform of cell-based assays and xenografts for compound screening; and licenses for access to several transgenic mouse models. Orphan Drug Legislation The US Orphan Drug Legislation, designed to foster drug development for disorders with patient populations under 200,000 in the US, provides tax incentives, seven (7) years of exclusive rights to the market, priority review status with the FDA and reduced requirements for clinical trials. These advantages are expected to keep development costs down and to decrease the time it takes to get products to market. Of the 6,000 disorders covered by the Orphan Drug Legislation, NF is among the most common. NexGenix expects to apply for Orphan Drug Designation for NX101 by the third quarter of 2008. For more information please contact:Michelle Morin, Director of Corporate Development